Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
09 janv. 2020 10h24 HE
|
Retrotope
LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...
Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)
07 août 2019 10h00 HE
|
Retrotope
LOS ALTOS, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the...
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
19 juil. 2019 11h15 HE
|
Retrotope
LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
06 mai 2019 12h57 HE
|
Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)
13 mars 2019 13h23 HE
|
Retrotope
LOS ALTOS, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for...
UPDATE - Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
14 déc. 2018 15h50 HE
|
Retrotope
LOS ALTOS, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that it has begun enrollment of the first patients and has started dosing of infants with the ultra-rare...
Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
13 déc. 2018 12h16 HE
|
Retrotope
LOS ALTOS, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that it has begun enrollment of the first patients and has started dosing of infants with the ultra-rare...
Retrotope Presents Data Demonstrating Arrest of Disease Progression with Treatment of RT001 in Patients with Infantile Neuroaxonal Dystrophy (INAD)
15 oct. 2018 07h30 HE
|
Retrotope
Results presented at the 2018 National Organization for Rare Disorders (NORD) Rare Diseases & Orphan Products Breakthrough Summit® LOS ALTOS, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) --...
Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients
04 oct. 2018 08h00 HE
|
Retrotope
SUNNYVALE and LOS ALTOS, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Parkinson’s Institute and Clinical Center, which provides comprehensive patient care, while discovering new treatment options to...
Retrotope Announces the Initiation of Expanded Access (Compassionate Use) Trial of RT001 in Amyotrophic Lateral Sclerosis (ALS)
17 sept. 2018 08h00 HE
|
Retrotope
First ALS patient dosed with RT001 LOS ALTOS, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Retrotope today announced that it has supplied its drug RT001 for the initiation of an expanded access (EA)...